Literature DB >> 23165226

[Feasibility of laparoendoscopic single-site surgery in gynecology with conventional laparoscopic instruments].

L de Poncheville1, A Smirnoff, J Ménard, G Corbineau, V Vié-Buret, O Nohra, S Leyre, E Drapier.   

Abstract

OBJECTIVES: To describe the safety and efficacy of single-port access for laparoscopic surgery in gynecology with conventional laparoscopic instruments. PATIENTS AND METHODS: In this prospective study, we report our experience with 90 patients who underwent Single Port Access (SPA) laparoscopic surgery for gynecologic pathology with the use of the SILS(®) Port Multiple Instrument Access Port (Covidien(®), Mansfield, MA).
RESULTS: We realised 15 ovarian cystectomies, 30 salpingo-oophrectomies with 14 one side, 9 lysis of adhesions, 7 distal tubal repairs, 6 salpingectomy, 8 other procedures. The mean surgical time is 47 min (25-120). One conversion to conventional laparoscopy and one in laparotomy were performed. The mean duration stay is 2 days [1-3]. DISCUSSION AND
CONCLUSION: SPA in gynecology is feasible with conventional laparoscopic instruments. SPA surgery represents the newest frontier in minimally invasive surgery.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23165226     DOI: 10.1016/j.gyobfe.2012.09.003

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  2 in total

1.  Single incision laparoscopic surgery using conventional laparoscopic instruments versus two-port laparoscopic surgery for adnexal lesions.

Authors:  Kuan-Ju Huang; Kuan-Ting Lin; Chin-Jui Wu; Ying-Xuan Li; Wen-Chun Chang; Bor-Ching Sheu
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

2.  Effect of laparoscopy by single-port endoscopic access in benign adnexal surgery: study protocol for a randomized controlled trial.

Authors:  Andy Schmitt; Patrice Crochet; Karine Baumstark; Claire Tourette; Sabine Poizac; Audrey Pivano; Léon Boubli; Ludovic Cravello; Aubert Agostini
Journal:  Trials       Date:  2018-01-15       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.